XBiotech (XBiotech) Ending Cash Position : $200.02 Mil (As of Dec. 2023)

View and export this data going back to 2015. Start your Free Trial

What is XBiotech Ending Cash Position?

XBiotech's Ending Cash Position for the quarter that ended in Dec. 2023 was $200.02 Mil.

XBiotech's quarterly Ending Cash Position increased from Jun. 2023 ($143.39 Mil) to Sep. 2023 ($202.19 Mil) but then declined from Sep. 2023 ($202.19 Mil) to Dec. 2023 ($200.02 Mil).

XBiotech's annual Ending Cash Position declined from Dec. 2021 ($236.98 Mil) to Dec. 2022 ($157.31 Mil) but then increased from Dec. 2022 ($157.31 Mil) to Dec. 2023 ($200.02 Mil).

XBiotech Ending Cash Position Historical Data

The historical data trend for XBiotech's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

XBiotech Ending Cash Position Chart

XBiotech Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Ending Cash Position

Get a 7-Day Free Trial

714.59

237.37

236.98

157.31

200.02

XBiotech Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Ending Cash Position	Get a 7-Day Free Trial															157.31	152.48	143.39	202.19	200.02

XBiotech Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

XBiotech's Ending Cash Position for the fiscal year that ended in Dec. 2023 is calculated as

Ending Cash Position	=	Beginning Cash Position	+	Net Change in Cash
	=	157.306	+	42.717
	=	200.02

XBiotech's Ending Cash Position for the quarter that ended in Dec. 2023 is calculated as

Ending Cash Position	=	Beginning Cash Position	+	Net Change in Cash
	=	202.191	+	-2.168
	=	200.02

XBiotech Ending Cash Position Related Terms

Thank you for viewing the detailed overview of XBiotech's Ending Cash Position provided by GuruFocus.com. Please click on the following links to see related term pages.

XBiotech (XBiotech) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » XBiotech Inc (NAS:XBIT) » Definitions » Ending Cash Position

Comparable Companies

Traded in Other Exchanges

4XB:Germany 4XB:Germany

Address

5217 Winnebago Lane, Austin, TX, USA, 78744

Website

http://www.xbiotech.com

XBiotech Inc is a United States based clinical-stage biopharmaceutical company. It is engaged in discovering and developing True Human (antibody technology) monoclonal antibodies for treating a variety of diseases. The company focuses on developing Anti-IL-1 a therapeutic antibody as a treatment for cancer. Geographically, all of its operations are in the United States.

Executives

Angela Hu	officer: Principle Financial Officer	5217 WINNEBAGO LN, AUSTIN TX 78744
John Simard	director, 10 percent owner	8201 E RIVERSIDE DRIVE, BLDG 4, STE 100, AUSTIN TX 78744
Bay Street Financial S.a.	10 percent owner	MEIERHOFSTRASSE 5, LIECHTENSTEIN N2 9490 VADUZ
W Thorpe Mckenzie	director, 10 percent owner	735 BROAD ST, STE 1105, CHATTANOOGA TN 37402
Sushma Shivaswamy	officer: VP of R&D	8201 E RIVERSIDE DRIVE, BLDG 4, STE 100, AUSTIN TX 78744
Queena Han	officer: VP of Fin & HR, Secretary	8201 E RIVERSIDE DRIVE, BLDG 4 STE 100, AUSTIN TX 78744
Thomas Gut	10 percent owner	CO LINDENBERG FAMILY OFFICE LTD, LATERNENGASSE 5, ZURICH V8 8001
Peter Libby	director	109 LARCH ROAD, CAMBRIDGE MA 02138
Fondation Rennes	10 percent owner	RATIKONSTRASSE 13, VADUZ, PRINCIPALITY OF LIECHTENSTEIN N2 FL-9490
Donald H. Macadam	director	56 KELLY DRIVE, PORT DOVER A6 N0A 1N5
Jan-paul Waldin	director	77 KING STREET WEST, SUITE 3000, TORONTO A6 M5K 1G8
Benjamin Guzman	officer: Sr.VP Corp. Strategy & Finance	8201 E RIVERSIDE DR BLDG. 4 STE 100, AUSTIN TX 78744
Trey Benson	officer: VP of Commercial Development	8201 E. RIVERSIDE DR., BUILDING 4, SUITE 100, AUSTIN TX 78744
Kalidip Choudhury	officer: VP of Business Development	8201 E. RIVERSIDE DRIVE, BUILDING 4, SUITE 100, AUSTIN TX 78744
Dawn Mccollough	officer: VP Clinical Operations	115 SANDRA MURAIDA WAY, #838, AUSTIN TX 78703